AstraZeneca’s breast cancer drug Etcamah failed its first-line trial, SERENA-4, raising doubts about its potential as a frontline treatment for HR-positive pati
Novo Nordisk drops its full name to become 'Novo,' sharpening focus against Eli Lilly in weight loss and diabetes treatments amid slowing growth.
AbbVie’s Qulipta becomes first oral CGRP inhibitor to succeed in phase 3 menstrual migraine trials, offering hope for resistant cases.
Bayer secured FDA approval for Hyrnuo lung cancer treatment, marking a major shift in frontline HER2-mutant NSCLC care based on new clinical data.
Bristol Myers reports progress in multiple myeloma trial with arlocabtagene autoleucel showing promise.
Guidelines for e-signature use in global trials, including qualified e-signature and standard e-signature options.
Sensorion's HearConnex trial gets green light for hearing loss treatment with gene therapy SENS-601.
Alumis advances its lupus drug to Phase III trials despite mixed Phase IIb results, targeting a specific patient subgroup for better outcomes.
AstraZeneca's AZD5462 shows promise in Phase II trial for chronic heart failure, improving cardiac function via relaxin pathway.
Novartis announces positive Phase III results for Remibrutinib, a new oral treatment for relapsing multiple sclerosis showing significant efficacy over teriflun
© 2026 Vimeo Health. All rights reserved.
Theme by Auto UI Theme Builder.
